Regencell Bioscience Holdings (RGC) Assets (2020 - 2025)

Regencell Bioscience Holdings' (RGC) quarterly Assets came in at $3.0 million in Q4 2025, down 47.64% on a QoQ basis from $5.8 million in Q2 2025.

Regencell Bioscience Holdings (RGC) Assets (2020 - 2025) Analysis & Trends

Regencell Bioscience Holdings (RGC) has 3 years of Assets data on file, last reported at $3.0 million in Q4 2025.

Quarterly Assets changed N/A year-over-year to $3.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.8 million (changed N/A YoY) and the FY2025 annual result came in at $5.8 million, changed N/A from the prior year.
Assets fell to $3.0 million in Q4 2025, from $5.8 million in the prior quarter.
In the past five years, Assets ranged from a high of $12.6 million in Q2 2023 to a low of $3.0 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Assets (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-	43.71 Bn
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn	39.86 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn	15.08 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn	98.27 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn	7.22 Bn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn	35.04 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn	5.36 Bn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	13.56 Bn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	6.18 Bn
10	Regencell Bioscience Holdings	2.67 Bn	2.67 Bn	-	3.01 Mn

Download Data